ArticleInternational journal of radiation oncology, biology, physics2026
Geranylgeranyl Transferase Inhibitors Mitigate Intestinal Radiation Toxicity.
Article in International journal of radiation oncology, biology, physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeThe risk of large volume single radiation exposure from accidents, malicious activities, or therapeutic hemi-body irradiation is growing. Such exposures cause large-field irradiation or partial-body irradiation (PBI) that can damage the intestine. No medical countermeasures, referred to as radiation mitigators, are available to suppress intestinal radiation damage when administered after radiation exposure. METHODS AND MATERIALS: We investigated the efficacy of geranylgeranyl transferase inhibitors (GGTis), specifically GGTi-2133 (hereafter GGTi), to mitigate intestinal radiation injury in C57BL/6J mice after exposure to 12 or 13 Gy γ-rays with both hind limbs shielded. Starting 24 hours after PBI and every 48 hours thereafter, we administered either vehicle or GGTi via intraperitoneal injection and collected intestinal tissues on days 3.5 or 14 after 12 Gy PBI from male mice and on day 14 after 13 Gy PBI from female mice. Additionally, the effects of GGTi on endothelial cells after fractionated exposure and on primary intestinal organoids after single exposure were assessed.
resultsGGTi treatment increased the number of surviving crypts on day 3.5 after PBI in male mice. In addition, in both sexes, GGTi mitigated intestinal structural damage on day 14. Additionally, GGTi mitigated manifestations of PBI-induced intestinal injury including crypt proliferation; a decrease in the number of mucus-secreting cells and mucus secretion; alterations in stem cell markers at mRNA and protein levels; changes in intestinal neutrophil, lymphocyte, and macrophage counts; and alterations in intestinal vascular endothelial cell markers on day 14 after 12 Gy PBI in male mice. Finally, ex vivo mechanistic studies revealed that GGTi prevents suppression of key beneficial molecules in the human primary endothelial cells and upregulates key molecules essential for intestinal homeostasis and maintenance of intestinal stem cells in the murine intestinal organoids following irradiation.
conclusionsAltogether, our study demonstrates that GGTi is a potent mitigating agent against intestinal radiation toxicity by modifying multiple cell types.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.